Myriad Genetics (NASDAQ:MYGN) Announces Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Myriad Genetics (NASDAQ:MYGN) announced its quarterly earnings data on Tuesday. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.03), FiscalAI reports. Myriad Genetics had a negative net margin of 48.24% and a negative return on equity of 8.29%. The business had revenue of $200.40 million for the quarter, compared to analysts’ expectations of $202.42 million. During the same period in the prior year, the company posted ($0.03) EPS. The firm’s revenue was up 2.3% on a year-over-year basis.

Here are the key takeaways from Myriad Genetics’ conference call:

• The company reaffirmed full?year 2026 guidance with revenue of $860–$880M, adjusted gross margin of 68%–69%, and adjusted EBITDA of $37–$49M, after reporting Q1 revenue of $200.4M.
• Alpha commercialization of Precise MRD (breast) is underway with ~12 onboarded sites, strong assay yield and turnaround times, and the company has accelerated select colorectal and renal rollouts toward broader commercialization into 2026–2027.
• Management is investing $35M over several years and has added over 100 account executives focused on the cancer care continuum and prenatal channels, which should support launches but will take several quarters to reach full productivity and has driven higher near?term OpEx.
• Prenatal revenue declined ~15% YoY to $41.9M due to prior ordering disruptions and account losses; management expects stabilization and a return to growth in H2 2026 driven by the FirstGene launch but the segment remains a near?term headwind.
• GeneSight delivered strong performance with revenue up 24% YoY to $38.3M (7% volume growth), aided by improved reimbursement and a record ~39,000 ordering clinicians, supporting margin improvement.

Myriad Genetics Trading Down 0.5%

Shares of NASDAQ:MYGN traded down $0.02 during mid-day trading on Thursday, reaching $4.09. 2,547,180 shares of the company were exchanged, compared to its average volume of 1,588,701. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.49 and a quick ratio of 2.26. The firm has a market cap of $386.27 million, a price-to-earnings ratio of -0.95 and a beta of 1.81. The firm’s 50-day simple moving average is $4.78 and its 200 day simple moving average is $5.87. Myriad Genetics has a 1 year low of $3.75 and a 1 year high of $8.59.

Analyst Ratings Changes

MYGN has been the subject of several research reports. Zacks Research raised shares of Myriad Genetics from a “strong sell” rating to a “hold” rating in a research note on Thursday, February 26th. UBS Group dropped their price target on shares of Myriad Genetics from $8.00 to $6.00 and set a “neutral” rating for the company in a research note on Tuesday, February 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Myriad Genetics in a research note on Friday, March 27th. TD Cowen dropped their price target on shares of Myriad Genetics from $7.00 to $6.00 and set a “hold” rating for the company in a research note on Wednesday. Finally, Wells Fargo & Company dropped their price target on shares of Myriad Genetics from $6.00 to $5.50 and set an “equal weight” rating for the company in a research note on Wednesday. One investment analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $6.40.

Insider Buying and Selling

In related news, CEO Samraat S. Raha acquired 40,000 shares of the stock in a transaction that occurred on Monday, March 9th. The stock was purchased at an average price of $5.00 per share, with a total value of $200,000.00. Following the transaction, the chief executive officer owned 493,104 shares of the company’s stock, valued at approximately $2,465,520. This trade represents a 8.83% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director S. Louise Phanstiel acquired 50,407 shares of the stock in a transaction that occurred on Thursday, February 26th. The shares were bought at an average cost of $4.80 per share, with a total value of $241,953.60. Following the transaction, the director directly owned 233,951 shares in the company, valued at $1,122,964.80. This trade represents a 27.46% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 144,507 shares of company stock valued at $694,548 in the last ninety days. 1.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Myriad Genetics

A number of hedge funds have recently made changes to their positions in MYGN. EverSource Wealth Advisors LLC boosted its position in shares of Myriad Genetics by 2,333.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 4,672 shares of the company’s stock worth $25,000 after purchasing an additional 4,480 shares during the period. Quarry LP lifted its holdings in Myriad Genetics by 155.6% during the 4th quarter. Quarry LP now owns 4,365 shares of the company’s stock worth $27,000 after buying an additional 2,657 shares in the last quarter. Royal Bank of Canada lifted its holdings in Myriad Genetics by 129.6% during the 4th quarter. Royal Bank of Canada now owns 4,993 shares of the company’s stock worth $31,000 after buying an additional 2,818 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Myriad Genetics during the 2nd quarter worth approximately $37,000. Finally, American Century Companies Inc. acquired a new stake in Myriad Genetics during the 2nd quarter worth approximately $55,000. Hedge funds and other institutional investors own 99.02% of the company’s stock.

Myriad Genetics Company Profile

Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual’s risk for various hereditary conditions and to guide personalized treatment decisions. The company’s core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women’s health, neurology and pharmacogenomics to support more informed clinical decision-making.

Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities.